all-trans retinoic acid boosts the efficacy of sorafenib against liver cancer
Published 1 year ago • 175 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:17
inhibiting dkk1 enhances sorafenib efficacy in hcc
-
6:02
hcc: considerations in first-line use of sorafenib
-
1:10
real life analysis shows regorafenib improves survival upon progression on sorafenib in hcc
-
2:53
efficacy of sorafenib in advanced hepatocellular carcinoma - seer data analysis
-
8:10
dosing strategies with sorafenib in hcc
-
1:11
regorafenib vs sorafenib in the treatment of liver cancer
-
0:11
sorafina (sorafenib) kidney cancer, liver cancer, and thyroid cancer medicine
-
2:28
nrg/rtog 1112: sorafenib vs sbrt followed by sorafenib in hcc
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
5:40
sorafenib initiation after tace in hcc
-
5:16
transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma
-
1:02
dr. kudo discusses tace plus sorafenib in hcc
-
5:28
assessing response to sorafenib
-
1:34
dr. finn on the promise of regorafenib for the treatment of hcc
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
1:57
dr. abou-alfa on doxorubicin plus sorafenib in hcc
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
3:05
imbrave150: updated data on atezo plus bev versus sorafenib in hcc